aibio
Listings ·
Xenetic files investor presentation on proposed transaction with Santersus
The September 2026 deck's risk list includes a possible reverse stock split to meet Nasdaq listing requirements.
XBIO Xenetic Biosciences, Inc.
Xenetic Biosciences (XBIO) news XBIO reverse split, offering and merger news
Latest Xenetic Biosciences news
- Financings
Xenetic Biosciences agrees to acquire Santersus AG in all-stock share exchange
The deal needs Xenetic stockholder approval. Pro forma, current Xenetic holders would own approximately 15.0% and Santersus holders approximately 85.0%.
- Financings
Xenetic Biosciences prices $4.5 million offering of 735,000 shares at $6.12
Canaccord Genuity is sole bookrunner. Xenetic plans to use net proceeds for working capital and general corporate purposes.
Xenetic Biosciences annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $3.0 million | $2.5 million |
| Research and development | $3.1 million | $3.3 million |
| Net income (loss) | -$2.7 million | -$4.0 million |
| Cash from operations | -$2.3 million | -$2.8 million |
| Cash and equivalents | $7.9 million | $6.2 million |
Questions about Xenetic Biosciences
Did Xenetic Biosciences do a reverse stock split?
Our latest story on this, dated Sep 23, 2026: "Xenetic files investor presentation on proposed transaction with Santersus". The story links the filing or release it is based on. Read the story.
Has Xenetic Biosciences raised money recently?
Our latest story on this, dated Oct 10, 2025: "Xenetic Biosciences prices $4.5 million offering of 735,000 shares at $6.12". The story links the filing or release it is based on. Read the story.
Is Xenetic Biosciences involved in a merger or acquisition?
Our latest story on this, dated Sep 16, 2026: "Xenetic Biosciences agrees to acquire Santersus AG in all-stock share exchange". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Xenetic Biosciences?
Xenetic Biosciences, Inc. trades under the ticker XBIO on NASDAQ.
Where is Xenetic Biosciences listed?
Xenetic Biosciences, Inc. is listed on NASDAQ.
What is the SEC CIK of Xenetic Biosciences?
The SEC Central Index Key (CIK) for Xenetic Biosciences, Inc. is 1534525. Its filings are on SEC EDGAR.
How many shares does Xenetic Biosciences have outstanding?
2,343,181 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06.
Which country or territory is Xenetic Biosciences listed under?
Our directory records Xenetic Biosciences, Inc. under United States.
What does Xenetic Biosciences do?
Our directory classifies Xenetic Biosciences, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Xenetic Biosciences?
The ISIN recorded for Xenetic Biosciences, Inc. is US9840156023.
Does aibio.space cover Xenetic Biosciences?
aibio.space lists Xenetic Biosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Xenetic Biosciences incorporated?
SEC records list its state or country of incorporation as NV.
What was Xenetic Biosciences's revenue last year?
$3.0 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Xenetic Biosciences profitable?
Xenetic Biosciences, Inc. reported a net loss of $2.7 million for the fiscal year ended Dec 31, 2025, and used $2.3 million of cash in operations, per its annual report to the SEC.
How much does Xenetic Biosciences spend on research and development?
$3.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
Investor discussion: Xenetic Biosciences
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 7.01,9.01). Source
- Financings
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
- Financings
Reported a financing. SEC Form 424B5. Source
- Legal
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Stock chart
SEC filings and registration
- SEC name
- Xenetic Biosciences, Inc.
- CIK
- 1534525
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- XBIO (Nasdaq)
- State or country of incorporation
- NV
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 945 CONCORD ST., FRAMINGHAM, MA, 01701
- Phone
- 781-778-7720
- Shares outstanding
- 2,343,181 as of 2026-07-31 (10-Q filed 2026-08-06)
- Former names
- General Sales & Leasing, Inc.; GENERAL AIRCRAFT INC.
Recent filings
Listing details
- Company
- Xenetic Biosciences, Inc.
- Ticker
- XBIO
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US9840156023
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction